PLURISTEM THERAPEUTICS INC (PSTI) Stock Price & Overview
NASDAQ:PSTI • US72940R3003
Current stock price
The current stock price of PSTI is 1 USD. Today PSTI is down by -2.91%. In the past month the price decreased by -21.26%. In the past year, price decreased by -69.51%.
PSTI Key Statistics
- Market Cap
- 32.348M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.47
- Dividend Yield
- N/A
PSTI Stock Performance
PSTI Stock Chart
PSTI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PSTI. When comparing the yearly performance of all stocks, PSTI is a bad performer in the overall market: 93.07% of all stocks are doing better.
PSTI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PSTI. PSTI has an excellent profitability rating, but there are some minor concerns on its financial health.
PSTI Earnings
PSTI Forecast & Estimates
8 analysts have analysed PSTI and the average price target is 3.57 USD. This implies a price increase of 257% is expected in the next year compared to the current price of 1.
PSTI Groups
Sector & Classification
PSTI Financial Highlights
Over the last trailing twelve months PSTI reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 9.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20373.91% | ||
| ROA | 59.22% | ||
| ROE | 123.02% | ||
| Debt/Equity | 0.6 |
PSTI Ownership
PSTI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 362.828B | ||
| AMGN | AMGEN INC | 15.51 | 187.828B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 171.453B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 113.963B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 78.412B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.05 | 40.854B | ||
| INSM | INSMED INC | N/A | 29.992B | ||
| NTRA | NATERA INC | N/A | 27.569B | ||
| BIIB | BIOGEN INC | 11.77 | 26.995B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.13 | 23.31B | ||
| MRNA | MODERNA INC | N/A | 20.276B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.929B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PSTI
Company Profile
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Company Info
IPO: 2007-12-10
PLURISTEM THERAPEUTICS INC
Building No. 5, Matam Advanced Technology Park
Haifa 3508409 IL
CEO: Yaky Yanay
Employees: 129
Phone: 972747107171.0
PLURISTEM THERAPEUTICS INC / PSTI FAQ
What does PLURISTEM THERAPEUTICS INC do?
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
What is the stock price of PLURISTEM THERAPEUTICS INC today?
The current stock price of PSTI is 1 USD. The price decreased by -2.91% in the last trading session.
Does PLURISTEM THERAPEUTICS INC pay dividends?
PSTI does not pay a dividend.
What is the ChartMill rating of PLURISTEM THERAPEUTICS INC stock?
PSTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is PLURISTEM THERAPEUTICS INC (PSTI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PSTI.
What is the employee count for PSTI stock?
PLURISTEM THERAPEUTICS INC (PSTI) currently has 129 employees.
What is the ownership structure of PLURISTEM THERAPEUTICS INC (PSTI)?
You can find the ownership structure of PLURISTEM THERAPEUTICS INC (PSTI) on the Ownership tab.